Tasquinimod is a new immunomodulatory treatment for MM that is in phase I/II clinical evaluation in patients with relapsed/refractory MM. In the present study, we evaluated the effect of tasquinimod on MM cells using RNA sequencing to provide more mechanistic insights into the observed tasquinimod-m...
The quinoline-3-carboxamide ABR-215050 (Tasquinimod (INN)), exhibits anti-tumor activity via inhibition of tumor angiogenesis in human and rodent tumors. To further explore the mode of action of ABR-215050, in vivo experiments with gene microarray analysis were performed using samples of LNCaP prost...
